Phase I drug-food interaction trial of tivantinib.
Latest Information Update: 02 Apr 2012
Price :
$35 *
At a glance
- Drugs Tivantinib (Primary)
- Indications Colorectal cancer; Gastric cancer; Germ cell cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Soft tissue sarcoma
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Europe
- 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.
- 31 Mar 2012 New trial record
- 29 Mar 2012 Results will be presented at AACR-2012 according to an ArQule media release.